Sunil Chauhan

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company based in Medfield, MA. Aramis Biosciences is committed to developing disease-modifying therapy for ocular surface disease, starting with dry eye disease. The company's lead product candidate, A197, is a novel, first-in-class, topical immunomodulatory agent currently in a phase II clinical proof of concept for the treatment of dry eye disease. The company was founded in 2018 by Sunil Chauhan, Reza Dana, and the CEO is David S. Tierney. Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation, and immunology from the Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, with support from Safar Partners, Dompé Farmaceutici S.p.A., and a leader in ophthalmic pharmaceuticals.